NEW YORK (GenomeWeb News) – Transgenomic today said that total revenue declined 10 percent in the second quarter and net loss narrowed 62 percent.
 
Receipts for the second quarter ended June 30 slid to $6.2 million from $6.9 million in the same quarter last year.
 
The company spent about $531,000 on R&D in the second quarter, down 9 percent from $581,000 in the comparable period last year.
 
Transgenomic said net loss shrank to $383,000 from $998,000 in Q2 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.